Rocket Pharmaceuticals (RCKT) Equity Average (2016 - 2025)
Historic Equity Average for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $333.9 million.
- Rocket Pharmaceuticals' Equity Average fell 651.25% to $333.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $333.9 million, marking a year-over-year decrease of 651.25%. This contributed to the annual value of $477.9 million for FY2024, which is 269.3% down from last year.
- According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Equity Average is $333.9 million, which was down 651.25% from $383.2 million recorded in Q2 2025.
- In the past 5 years, Rocket Pharmaceuticals' Equity Average ranged from a high of $516.8 million in Q4 2023 and a low of $333.9 million during Q3 2025
- Its 5-year average for Equity Average is $434.8 million, with a median of $436.2 million in 2022.
- As far as peak fluctuations go, Rocket Pharmaceuticals' Equity Average surged by 9181.04% in 2021, and later crashed by 2432.59% in 2024.
- Quarter analysis of 5 years shows Rocket Pharmaceuticals' Equity Average stood at $470.2 million in 2021, then dropped by 8.87% to $428.5 million in 2022, then increased by 20.61% to $516.8 million in 2023, then decreased by 23.28% to $396.5 million in 2024, then fell by 15.78% to $333.9 million in 2025.
- Its Equity Average stands at $333.9 million for Q3 2025, versus $383.2 million for Q2 2025 and $437.7 million for Q1 2025.